Abstract
The efficacy of an active compound can be advantageously improved when combined with other active compounds. Medicinal products for a particular indication(s) that contain combination of two or more active compounds in a fixed dose ratio is so called fixed-dose combination medicinal products or FDCs. FDCs are beneficial for patients’ adherence to the treatment because of the simplified drug regimen. They are used in the treatment of a wide range of medical conditions especially in the treatment of chronic illnesses including AIDS, type 2 diabetes, and many cardiovascular diseases. FDCs as other medicines are subject to variety of intellectual property rights protection (IPRs), including patents and data protection. Different jurisdictions worldwide have different standards when determining the eligibility of FDCs for patent and/or data protection. They can vary from 1) cases with lower standards for assessing the inventive step, where FDCs are given additional combination patent rights, 2) cases where FDCs is given status of new chemical entities thus allowing supplementary protection certificates and 3) cases where additional data protection for FDCs of already known active compounds is allowed. In this study, we have assessed the national standards among different jurisdictions of developing and developed countries. A comparison of their approaches in respect to their benefits and deficiencies related to the originators, patient accessibility and public health policies has been made. Key words: Fixed-dose combination medicinal products, patents, data exclusivity
Highlights
The development of FDCs is becoming increasingly high either to improve compliance or to benefit from the added effects of the two or more active drugs given together
Different jurisdictions worldwide have different standards when determining the eligibility of FDCs for patent and/or data protection
A comparison of their approaches in respect to their benefits and deficiencies related to the originators, patient accessibility and public health policies has been made
Summary
The development of FDCs is becoming increasingly high either to improve compliance or to benefit from the added effects of the two or more active drugs given together. Each fixed dose combination should be carefully justified and clinically relevant (CDSCO, 2010; Gupta et al, 2016). The development of FDCs are becoming increasingly important from patient and public health perspectives because of the simplified drug regimen, less. Kikovska Stojanovska type 2 diabetes, and many cardiovascular diseases (CDSCO, 2010; FDA Center for Drug Evaluation and Research, 2014)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
